Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis-Reference-Cited by-同舟云学术

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis

Published:2019-05-06 Issue:8 Volume:26 Page:1027-1030
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Poordad Fred¹,Sedghi Shahriar²,Pockros Paul J.³,Ravendhran Natarajan⁴,Reindollar Robert⁵,Lucey Michael R.⁶,Epstein Michael⁷,Bank Leslie⁸,Bernstein David⁹,Trinh Roger¹⁰,Krishnan Preethi¹⁰,Polepally Akshanth R.¹⁰,Unnebrink Kristina¹¹,Martinez Marisol¹⁰,Nelson David R.¹²

Affiliation:

1. Texas Liver Institute University of Texas Health San Antonio Texas

2. Mercer University School of Medicine Macon Georgia

3. Division of Gastroenterology/Hepatology Scripps Clinic La Jolla California

4. Digestive Disease Associates Baltimore Maryland

5. Piedmont Healthcare/Carolinas Center for Liver Disease Statesville North Carolina

6. Division of Gastroenterology/Hepatology, Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin

7. Anne Arundel Medical Center Digestive Disorders Associates Annapolis Maryland

8. Regional Clinical Research Inc Endwell New York

9. Hofstra Northwell School of Medicine Manhasset New York

10. AbbVie Inc. North Chicago Illinois

11. AbbVie Deutschland GmbH & Co. KG Ludwigshafen Germany